Cowen and Company’s Calidi Biotherapeutics CLDI Stock Holding History

Cowen and Company’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-755	Closed	-$893K	–	687
2022 Q3	$893K	Buy	+755	New	+$905K	0.09%	88

Other funds holding CLDI

Hudson Bay Capital Management

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Bank of Montreal

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Elequin Capital New York $1.19B AUM 16.08% 1-Year Est. Return

Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return

Cowen and Company's CLDI Position: Q4 2022 in Review

Cowen and Company sold out of Calidi Biotherapeutics (CLDI) in Q4 2022, closing a stake of 755 shares — an estimated $893K sold.

Cowen and Company first reported a position in CLDI in Q3 2022 and held it in 1 quarter. The position peaked at $893K in Q3 2022. 24 funds tracked by Wall St. Rank hold CLDI as of Q4 2022.

Cowen and Company reported no remaining Calidi Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Cowen and Company sold 755 Calidi Biotherapeutics shares in Q4 2022, an estimated $893K.
Cowen and Company first reported a position in Calidi Biotherapeutics in Q3 2022 and held it in 1 quarter.
Cowen and Company's Calidi Biotherapeutics position peaked at $893K in Q3 2022.
24 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q4 2022.

Based on Cowen and Company's 13F filing for Q4 2022, filed 9 Feb 2023.